ArticleFrontiers in pharmacology2025
Navigating barriers to real-world evidence utilization for drug regulatory affairs and market access in Saudi Arabia.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data-driven, evidence-based decision-making is crucial for guiding complex and often conflicting decision-making in health systems. This study explored the barriers and challenges faced by stakeholders in generating and using real-world evidence (RWE) in Saudi Arabia, focusing on pharmaceutical regulatory, reimbursements, and research landscapes. Methods: Semi-structured interviews were conducted with Saudi stakeholders working in regulatory organizations, research institutions, and the pharmaceutical industry using a topic guide. Purposeful sampling was used to select study participants. The interview topic guide included three main open-ended questions focused on the participants' current experiences, existing barriers, and potential interventions for overcoming challenges. Thematic analysis was used to identify barrier- and challenge-related themes and subthemes. Findings: 11 stakeholders working in regulatory organizations, research institutions, and the pharmaceutical industry across Saudi Arabia were interviewed. Based on the interviews, we identified four major themes pertaining to the barriers and challenges related to advancing RWE use in Saudi Arabia: data management, local capabilities, resources, and governance. Each theme contained key subthemes. Conclusion: This study reveals critical barriers to RWE generation and utilization in Saudi Arabia. Having clear governance, policies, and guidelines for the collection, standardization, sharing, and utilization of real-world data is crucial for overcoming these barriers and challenges. A multifaceted policy approach characterized by stakeholder engagement, collaboration, and coordinated implementation efforts could help build a robust, unified RWE system that aligns with the Saudi Vision 2030 objectives for a sustainable, data-driven healthcare ecosystem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.